<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marjan Van Blerk</style></author><author><style face="normal" font="default" size="100%">Bailleul, E</style></author><author><style face="normal" font="default" size="100%">Chatelain, B</style></author><author><style face="normal" font="default" size="100%">Demulder, A</style></author><author><style face="normal" font="default" size="100%">Devreese, K</style></author><author><style face="normal" font="default" size="100%">Douxfils, J</style></author><author><style face="normal" font="default" size="100%">Jacquemin, M</style></author><author><style face="normal" font="default" size="100%">Jochmans, K</style></author><author><style face="normal" font="default" size="100%">Mullier, F</style></author><author><style face="normal" font="default" size="100%">Wijns, W</style></author><author><style face="normal" font="default" size="100%">Bernard China</style></author><author><style face="normal" font="default" size="100%">Kris Vernelen</style></author><author><style face="normal" font="default" size="100%">Mohamed Rida Soumali</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Lab Hematol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Int J Lab Hematol</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Aug</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">39</style></volume><pages><style face="normal" font="default" size="100%">402-408</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;INTRODUCTION: &lt;/b&gt;The Belgian national External Quality Assessment Scheme performed a survey to assess the effect of the direct oral anticoagulant apixaban on the coagulation assays prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin as performed with a large number of reagent/instrument combinations.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Four lyophilized plasma samples spiked with apixaban (0, 41, 94 and 225 ng/mL) were sent to the 195 Belgian and Luxembourg clinical laboratories performing coagulation testing.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;PT and aPTT were barely influenced at the concentrations tested. At 225 ng/mL apixaban, PT and aPTT clotting times were only 1.15 times longer than at 0 ng/mL. Among PT reagents, RecombiPlasTin 2G(®) showed a slightly higher sensitivity with 225 ng/mL apixaban prolonging the PT clotting time 1.3-fold. Among aPTT reagents, there was no appreciable difference in sensitivity. Fibrinogen results were unaffected by the presence of apixaban, but antithrombin activity was considerably overestimated when measured with a FXa-based assay. At 225 ng/mL apixaban, the median percentage increase in antithrombin level was 31% when measured with the Liquid Antithrombin(®) reagent and 44% with the Innovance Antithrombin(®) reagent.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;Our data provide clinical laboratories with useful information on the impact of apixaban on their routine coagulation assays.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/28304137?dopt=Abstract</style></custom1></record></records></xml>